↓ Skip to main content

Reciprocal Binding of CTCF and BORIS to the NY-ESO-1 Promoter Coincides with Derepression of this Cancer-Testis Gene in Lung Cancer Cells

Overview of attention for article published in Cancer Research, September 2005
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (80th percentile)
  • Good Attention Score compared to outputs of the same age and source (69th percentile)

Mentioned by

twitter
1 tweeter
patent
3 patents
wikipedia
2 Wikipedia pages

Citations

dimensions_citation
153 Dimensions

Readers on

mendeley
73 Mendeley
citeulike
3 CiteULike
connotea
2 Connotea
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Reciprocal Binding of CTCF and BORIS to the NY-ESO-1 Promoter Coincides with Derepression of this Cancer-Testis Gene in Lung Cancer Cells
Published in
Cancer Research, September 2005
DOI 10.1158/0008-5472.can-05-0823
Pubmed ID
Authors

Julie A. Hong, Yang Kang, Ziedulla Abdullaev, Patrick T. Flanagan, Svetlana D. Pack, Maria R. Fischette, Mina T. Adnani, Dmitri I. Loukinov, Sergei Vatolin, John I. Risinger, Mary Custer, G. Aaron Chen, Ming Zhao, Dao M. Nguyen, J. Carl Barrett, Victor V. Lobanenkov, David S. Schrump

Abstract

Regulatory sequences recognized by the unique pair of paralogous factors, CTCF and BORIS, have been implicated in epigenetic regulation of imprinting and X chromosome inactivation. Lung cancers exhibit genome-wide demethylation associated with derepression of a specific class of genes encoding cancer-testis (CT) antigens such as NY-ESO-1. CT genes are normally expressed in BORIS-positive male germ cells deficient in CTCF and meCpG contents, but are strictly silenced in somatic cells. The present study was undertaken to ascertain if aberrant activation of BORIS contributes to derepression of NY-ESO-1 during pulmonary carcinogenesis. Preliminary experiments indicated that NY-ESO-1 expression coincided with derepression of BORIS in cultured lung cancer cells. Quantitative reverse transcription-PCR analysis revealed robust, coincident induction of BORIS and NY-ESO-1 expression in lung cancer cells, but not normal human bronchial epithelial cells following 5-aza-2'-deoxycytidine (5-azadC), Depsipeptide FK228 (DP), or sequential 5-azadC/DP exposure under clinically relevant conditions. Bisulfite sequencing, methylation-specific PCR, and chromatin immunoprecipitation (ChIP) experiments showed that induction of BORIS coincided with direct modulation of chromatin structure within a CpG island in the 5'-flanking noncoding region of this gene. Cotransfection experiments using promoter-reporter constructs confirmed that BORIS modulates NY-ESO-1 expression in lung cancer cells. Gel shift and ChIP experiments revealed a novel CTCF/BORIS-binding site in the NY-ESO-1 promoter, which unlike such sites in the H19-imprinting control region and X chromosome, is insensitive to CpG methylation in vitro. In vivo occupancy of this site by CTCF was associated with silencing of the NY-ESO-1 promoter, whereas switching from CTCF to BORIS occupancy coincided with derepression of NY-ESO-1. Collectively, these data indicate that reciprocal binding of CTCF and BORIS to the NY-ESO-1 promoter mediates epigenetic regulation of this CT gene in lung cancer cells, and suggest that induction of BORIS may be a novel strategy to augment immunogenicity of pulmonary carcinomas.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 73 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 3 4%
Mexico 1 1%
Netherlands 1 1%
Brazil 1 1%
Unknown 67 92%

Demographic breakdown

Readers by professional status Count As %
Researcher 19 26%
Student > Ph. D. Student 18 25%
Professor > Associate Professor 6 8%
Student > Postgraduate 4 5%
Student > Master 4 5%
Other 11 15%
Unknown 11 15%
Readers by discipline Count As %
Agricultural and Biological Sciences 31 42%
Biochemistry, Genetics and Molecular Biology 16 22%
Medicine and Dentistry 13 18%
Immunology and Microbiology 1 1%
Environmental Science 1 1%
Other 0 0%
Unknown 11 15%

Attention Score in Context

This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 July 2022.
All research outputs
#4,356,355
of 21,712,946 outputs
Outputs from Cancer Research
#4,276
of 17,474 outputs
Outputs of similar age
#63,254
of 326,339 outputs
Outputs of similar age from Cancer Research
#37
of 123 outputs
Altmetric has tracked 21,712,946 research outputs across all sources so far. Compared to these this one has done well and is in the 79th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 17,474 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.5. This one has done well, scoring higher than 75% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 326,339 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 80% of its contemporaries.
We're also able to compare this research output to 123 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 69% of its contemporaries.